# US 2003/0068320 A1 · Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0068320 A1
- Document ID: US20030068320A1
- Status: Published application
- Kind: A1
- Application number: 10/091,268
- Filed: 2002-03-04
- Published: 2003-04-10
- Earliest claimed: 2001-03-02
- Inventors: Christine Dingivan
- Web page: https://patentgrep.com/patent/US20030068320A1

## CPC

- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- A61K 39/39541: {against normal tissues, cells}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2806: {against CD2}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.

## Claims

### Claim 1

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising administering to a subject in need thereof a dose of a therapeutically effective amount of one or more CD2 binding molecules, wherein administration of said dose results in CD2 binding molecules binding to at least 25% of the CD2 polypeptides expressed by peripheral blood lymphocytes.

### Claim 2

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising administering to a subject in need thereof a dose of a therapeutically effective amount of one or more CD2 binding molecules, wherein administration of said dose results in a mean absolute lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl.

### Claim 3

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising administering to a subject in need thereof a dose of a therapeutically effective amount of one or more CD2 binding molecules, wherein administration of said dose results in an approximately 25% or more reduction in said subject's mean absolute lymphocyte count relative to said subject's mean absolute lymphocyte count prior to the administration of said dose.

### Claim 4 (depends on 2)

The method of claim 2 further comprising administering to said subject one or more subsequent doses of a therapeutically effective amount of one or more CD2 binding molecules after administration of said first dose, wherein administration of said subsequent doses maintain a mean absolute lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl.

### Claim 5 (depends on 2)

The method of claim 2 further comprising administering to said subject one or more subsequent doses of a therapeutically effective amount of one or more CD2 binding molecules after administration of said first dose, wherein administration of said subsequent doses maintain an approximately 25% or more reduction in said subject's absolute mean lymphocyte count relative to said subject's mean absolute lymphocyte count prior to the administration of said first dose.

### Claim 6 (depends on 4)

The method of claim 4, wherein said subsequent dose is administered at least 1 week after the administration of said first dose.

### Claim 7 (depends on 1)

The method of claim 1 further comprising administering to said subject one or more subsequent doses of a therapeutically effective amount of one or more CD2 binding molecules after administration of said first dose, wherein said administration of said subsequent doses restore at least 25% of the CD2 polypeptides expressed by peripheral blood lymphocytes being bound by CD2 binding molecules.

### Claim 8 (depends on 1, 3)

The method of claim 1 or 3, wherein said dose results in CD2 binding molecules binding to at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% or at least 80% of the CD2 polypeptides expressed by peripheral blood lymphocytes for at least 1 hour after the administration of said dose and prior to the administration of a subsequent dose.

### Claim 9 (depends on 7)

The method of claim 7, wherein said first dose results in CD2 binding molecules binding to at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% or at least 80% of the CD2 polypeptides expressed by peripheral blood lymphocytes.

### Claim 10 (depends on 7)

The method of claim 7, wherein said first dose results in a mean absolute lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl and said subsequent doses restore a mean absolute lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl.

### Claim 11 (depends on 3, 9)

The method of claim 3 or 9, wherein a subsequent dose is administered when the percentage of CD2 polypeptides bound to CD2 binding molecules drops to 20% or less, 15% or less, or 10% or less.

### Claim 12 (depends on 3, 9)

The method of claim 3 or 9, wherein a subsequent dose is administered when the mean absolute lymphocyte count increases to approximately 1250 cells/μl or more.

### Claim 13

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof said method comprising administering to a subject in need thereof a dose of a therapeutically effective amount of one or more CD2 binding molecules and administering to said subject one or more subsequent doses of a therapeutically effective amount of one or more CD2 binding molecules after administering a prior dose, wherein said CD2 binding molecules do not inhibit the interaction between LFA-3 and CD2.

### Claim 14 (depends on 1, 2, 3)

The method of claim 1, 2 or 3, wherein said CD2 binding molecules are not small organic molecules.

### Claim 15

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising:
(a) administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules;
(b) monitoring the mean absolute lymphocyte count in said subject after the administration of one or more of said doses and prior to the administration of a subsequent dose; and
(c) maintaining a mean absolute lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl by repeating step (a) as necessary.

### Claim 16

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising:
(a) administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules;
(b) monitoring the mean absolute lymphocyte count of said subject after the administration of one or more of said doses and prior to the administration of a subsequent dose; and
(c) maintaining a mean absolute lymphocyte count in said subject of 25% less than the mean absolute lymphocyte count in said subject prior to the administration of said doses of therapeutically effective amounts of one or more CD2 binding molecules by repeating step (a) as necessary.

### Claim 17

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising:
(a) administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules; and
(b) monitoring the mean absolute lymphocyte count in said subject after administration of a certain number of doses and prior to the administration of a subsequent dose.

### Claim 18 (depends on 17)

The method of claim 17, wherein the certain number of doses is 1, 2, 3, 4, 5, 6,7,8,9, 10, 11 or 12 doses.

### Claim 19 (depends on 18)

The method of claim 18 further comprising administering one or more subsequent doses of a therapeutically effective amount of one or more CD2 binding molecules based upon whether the lymphocyte count is within the range of approximately 500 cells/μl to 1200 cells/μl.

### Claim 20

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising:
(a) administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules;
(b) assessing the percentage of CD2 polypeptides bound by CD2 binding molecules after administration of one or more of said doses and prior to the administration of a subsequent dose; and
(c) administering to said subject one or more subsequent doses of a therapeutically effective amount of one or more CD2 binding molecules when the percentage of CD2 polypeptides expressed by peripheral blood lymphocytes bound by CD2 binding molecules is approximately 20% or less.

### Claim 21

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising:
(a) administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules;
(b) monitoring the percentage of CD2 polypeptides bound by CD2 binding molecules after administration of one or more of said doses and prior to the administration of a subsequent dose; and
(c) maintaining at least a 25% receptor occupancy by said CD2 binding molecules in said subject by repeating step (a) as necessary.

### Claim 22

A method of treating or ameliorating an autoimmune disorder or an inflammatory disorder or one or more symptoms thereof, said method comprising:
(a) administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules; and
(b) monitoring the percentage of CD2 polypeptides expressed by peripheral blood lymphocytes bound by CD2 binding molecules in said subject after administration of a certain number of doses and prior to the administration of a subsequent dose.

### Claim 23 (depends on 22)

The method of claim 22, wherein the certain number of doses is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 doses.

### Claim 24

A method of treating or ameliorating psoriasis or one or more symptoms thereof, said method comprising administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules, wherein administration of said doses results in a mean absolute lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl.

### Claim 25

A method of treating or ameliorating psoriasis or one or more symptoms thereof, said method comprising administering to a subject in need thereof one or more doses of a therapeutically effective amount of one or more CD2 binding molecules, wherein administration of said doses results in at least 25% of CD2 polypeptides expressed by peripheral blood lymphocytes being bound by CD2 binding molecules.

### Claim 26 (depends on 25)

The method of claim 25, wherein said doses result in CD2 binding molecules binding to at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% or at least 80% of the CD2 polypeptides expressed by peripheral blood lymphocytes.

### Claim 27

A method of treating or ameliorating psoriasis or one or more symptoms thereof, said method comprising administering to a subject in need thereof one or more doses of a therapeutically effective amount of MEDI-507.

### Claim 28 (depends on 27)

The method of claim 27, wherein administration of said doses results in a lymphocyte count of approximately 500 cells/μl to below 1200 cells/μl.

### Claim 29 (depends on 27)

The method of claim 27, wherein administration of said doses results in at least 30% of CD2 polypeptides expressed by peripheral blood lymphocytes being bound by MEDI-507.

### Claim 30 (depends on 29)

The method of claim 29, wherein said doses result in at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% or at least 80% of the CD2 polypeptides expressed by peripheral blood lymphocytes being bound by MEDI-507.

### Claim 31 (depends on 24, 25, 26, 27, 28)

The method of claim 24, 25, 26, 27 or 28, wherein at least a 25% reduction of said subject's Psoriasis Area and Severity Index (PASI) score is achieved.

### Claim 32 (depends on 31)

The method of claim 31, wherein the PASI score is reduced by at least 50%.

### Claim 33 (depends on 31)

The method of claim 31, wherein the PASI score is reduced by at least 75%.

### Claim 34

A method of treating or ameliorating psoriasis in a human which method reduces or avoids adverse effects associated with decreasing lymphocyte counts, said method comprising administering doses of a therapeutically effective amount of one or more CD2 binding molecules, said doses being effective to achieve a reduction in said human's PASI score by at least 25% but insufficient to cause a reduction in lymphocyte count to below 500 cells/μl.

### Claim 35 (depends on 34)

The method of claim 34, wherein at least a 50% reduction in said human's PASI score is achieved.

### Claim 36 (depends on 34)

The method of claim 34, wherein the lymphocyte count is between 500 cells/μl and 1200 cells/μl.

### Claim 37 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17 and 22, wherein the autoimmune disorder is rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Reiter's Syndrome, systemic lupus erythematosus, dermatomyositis, Sjögren's syndrome, lupus erythematosus, multiple sclerosis, or myasthenia gravis.

### Claim 38 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17 and 22, wherein the inflammatory disorder is asthma, encephilitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), arthritis, or an allergic disorder.

### Claim 39 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17 and 22, wherein the autoimmune disorder is characterized by increased infiltration of lymphocytes into affected dermal or epidermal tissues.

### Claim 40 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17 and 22, wherein the autoimmune disorder is characterized by increased T cell activation or abnormal antigen presentation.

### Claim 41 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17 and 22, wherein the autoimmune disorder is psoriasis.

### Claim 42 (depends on 41)

The method of claim 41, wherein the psoriasis is chronic plaque psoriasis.

### Claim 43 (depends on 1, 2, 3, 13)

The method of claim 1, 2, 3 or 13, wherein said dose is administered parenterally.

### Claim 44 (depends on 27, 28, 29)

The method of claim 27, 28 or 29, wherein said doses of MEDI-507 are administered parenterally.

### Claim 45 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17, 22, and 24, wherein at least one of the CD2 binding molecules is a fusion protein.

### Claim 46 (depends on 1, 2, 3, 4, 5, 13, 17, 22)

The method as in any one of claims 1-5, 13, 17, 22, and 24, wherein at least one of the CD2 binding molecules is an antibody.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody is LO-CD2a/BTI-322 or an antigen-binding fragment thereof.

### Claim 48 (depends on 46)

The method of claim 46, wherein the antibody is a human or humanized monoclonal antibody.

### Claim 49 (depends on 46)

The method of claim 46, wherein the antibody is MEDI-507 or an antigen-binding fragment thereof.

### Claim 50 (depends on 1, 2, 3, 4, 5, 13, 17, 22, 24)

The method as in any one of claims 1-5, 13, 17, 22, 24, and 27-29, wherein said effective amount is a dose of approximately 150 μg/kg or less, approximately 125 μg/kg or less, approximately 100 μg/kg or less, approximately 75 μg/kg or less, approximately 50 μg/kg or less, approximately 40 μg/kg or less, approximately 30 μg/kg or less, approximately 20 μg/kg or less, approximately 10 μg/kg or less, approximately 5 μg/kg or less, approximately 2 μg/kg or less, approximately 1 μg/kg or less, or approximately 0.5 μg/kg or less.

### Claim 51 (depends on 1, 2, 3, 4, 5, 13, 17, 22, 24)

The method as in any one of claims 1-5, 13, 17, 22, 24, and 27-29, wherein said effective amount is a dose of between approximately 0.05 μg/kg and 150 μg/kg.

### Claim 52 (depends on 1, 2, 3, 4, 5, 13, 17, 22, 24)

The method as in any one of claims 1-5, 13, 17, 22, 24, and 27-29, wherein the subject is a human subject.

### Claim 53 (depends on 4, 5)

The method of claim 4, 5, or 7, wherein the first dose is administered parenterally.

### Claim 54 (depends on 4, 5)

The method of claim 4, 5, or 7, wherein the subsequent doses are administered parenterally.

### Claim 55 (depends on 1, 2, 3, 13)

The method of claim 1, 2, 3 or 13, wherein said dose is administered subcutaneously.

### Claim 56 (depends on 27, 28, 29)

The method of claim 27, 28 or 29, wherein said doses of MEDI-507 are administered subcutaneously.

### Claim 57 (depends on 4, 5)

The method of claim 4, 5, or 7, wherein the first dose is administered subcutaneously.

### Claim 58 (depends on 4, 5)

The method of claim 4, 5, or 7, wherein the subsequent doses are administered subcutaneously.

### Claim 59

An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material,
wherein said pharmaceutical agent comprises a CD2 binding molecule and a pharmaceutically acceptable carrier,
wherein said article of manufacture includes instruction means indicating a dosing regimen comprising administering an initial dosing, and optionally administering a subsequent dose or doses, of said pharmaceutical agent to a subject suffering from one or more symptoms associated with an autoimmune disorder or an inflammatory disorder,
wherein the instruction means suggests a dosing regimen comprising an initial dosing that results in CD2 binding molecules binding to at least 30% of the CD2 polypeptides expressed by the subject's peripheral blood lymphocytes for at least 1 hour after the administration of said initial dosing, and
wherein the instruction means suggests a dosing interval for said dosing regimen such that any dose/doses administered subsequent to said initial dosing, if administered, is/are only administered when 20% or less of the CD2 polypeptides expressed by peripheral blood lymphocytes are bound by previously administered CD2 binding molecules.

### Claim 60

An article of manufacture comprising packaging material and a pharmaceutical composition in suitable form for administration to a human contained within said packaging material, wherein said pharmaceutical composition comprises MEDI-507 or an antigen-binding fragment thereof, and a pharmaceutically acceptable carrier.
